Dr. Jeffrey H. Margolis, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 898
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MI license 4301075311
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beaumont Hospital Royal Oak Royal Oak, MI
- Beaumont Hospital, Troy Troy, MI
- Beaumont Hospital - Dearborn Dearborn, MI
- Beaumont Hospital - Grosse Pointe Grosse Pointe, MI
- Beaumont Hospital - Farmington Hills Farmington Hills, MI
Medical groups
- Michigan Healthcare Professionals PC (529 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 898
- Services billed
- 385,662
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 46,020 | 11 |
| Injection, pembrolizumab, 1 mg | 29,600 | 24 |
| Injection, fosaprepitant, 1 mg | 28,500 | 48 |
| Injection, oxaliplatin, 0.5 mg | 24,100 | 15 |
| Injection, denosumab, 1 mg | 18,120 | 81 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 17,340 | 19 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 12,000 | 54 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 6,664 | 12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 5,398 | 83 |
| Injection, palonosetron hcl, 25 mcg | 3,200 | 72 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Madison Heights, MI | 729 |
| Dexamethasone Other prescribers in Madison Heights, MI | 464 |
| Prednisone Other prescribers in Madison Heights, MI | 290 |
| Eliquis (apixaban) Other prescribers in Madison Heights, MI | 219 |
| Olanzapine Other prescribers in Madison Heights, MI | 196 |
| Abiraterone Acetate | 162 |
| Imbruvica (ibrutinib) | 144 |
| Anastrozole Other prescribers in Madison Heights, MI | 137 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Madison Heights, MI | 133 |
| Levothyroxine Sodium Other prescribers in Madison Heights, MI | 131 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $288 in total to this clinician.
| Genmab U.S., Inc. | $132 |
|---|---|
| Avyxa Pharma, LLC | $132 |
| Sumitomo Pharma America, Inc. | $24.30 |
| Food and Beverage | $264 |
|---|---|
| Education | $24.30 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. May 14, 2025 | Education ORGOVYX · PROSTATE CANCER · in-kind | $24.30 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $462,993 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Part…
Merck Sharp & Dohme LLC - A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adeno…
AstraZeneca Pharmaceuticals LP - A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treat…
AstraZeneca Pharmaceuticals LP - A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Genzyme Corporation · Active, not recruiting · NCT06356571 - A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with loc…
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.